Replies to post #194034 on Biotech Values

[DewDiligence]

CLVS, Roche ink clinical-trial collaboration for Atezolizumab (PD-L1) + Rociletinib in EGFR-mutant NSCLC:

http://finance.yahoo.com/news/clovis-oncology-enters-clinical-trial-123000743.html

Yet another collaboration in which no cash in changing hands.

[DewDiligence]

CLVS—PDUFA date for Rociletinib in T790M+ NSCLC is 3/30/16 (with priority review):

http://finance.yahoo.com/news/clovis-oncology-announces-u-e-200100883.html

Also, the EMA will conduct an accelerated assessment.